Related Experiment Video
Updated: May 14, 2026
06:08
Formulating and Characterizing an Exosome-based Dopamine Carrier System
Published on: April 4, 2022
Engineered Exosomes: Innovative Strategies for Precision Drug Delivery in Parkinson's Disease.
Xinyu Yuan1, Cancan Wang1, Jie Yan1
1Guangxi University Medical College, No.100, Da-Xue-Dong Road, Nanning, 530004, Guangxi, China.
Molecular Neurobiology
|May 13, 2026
Summary
Exosomes show promise for Parkinson's disease (PD) therapy by crossing the blood-brain barrier. Engineering exosomes can deliver neuroprotective agents, but challenges remain for clinical use.
Area of Science:
- Neuroscience
- Biotechnology
- Pharmacology
Background:
- Parkinson's disease (PD) involves neuron loss, alpha-synuclein aggregation, and neuroinflammation.
- Current PD treatments offer symptomatic relief but don't stop disease progression due to the blood-brain barrier.
- Exosomes, nanoscale vesicles, can cross the blood-brain barrier and have dual roles in PD pathology and therapy.
Purpose of the Study:
- To review exosome engineering strategies for Parkinson's disease treatment.
- To highlight methods for surface modification and cargo loading in exosomes.
- To discuss challenges and future directions for clinical translation of exosome-based therapies.
Main Methods:
- Review of current literature on exosome engineering for neurodegenerative diseases.
- Analysis of exosome properties relevant to blood-brain barrier penetration and therapeutic cargo delivery.
- Examination of strategies for surface modification and internal loading of exosomes.
Main Results:
- Exosomes can be engineered to carry therapeutic agents (neurotrophic factors, microRNAs, drugs) for neuroprotection and anti-inflammation.
- Exosomes play a dual role in PD, propagating pathology and amplifying inflammation, but can be harnessed for therapeutic benefit.
- Challenges include delivery efficiency, brain accumulation, immunogenicity, heterogeneity, and regulatory hurdles.
Conclusions:
- Exosome engineering offers a promising avenue for Parkinson's disease therapy, potentially overcoming the blood-brain barrier.
- Further research is needed to optimize targeting, delivery, production, and address regulatory issues for clinical application.
- Advancements in exosome technology are crucial for developing personalized and regenerative medicine approaches for Parkinson's disease.
Related Concept Videos
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
01:36Overview of Exosomes
Exosomes are stable, lipid bilayer-enclosed vesicles capable of crossing biological barriers. They can carry a wide range of molecules required for intercellular communication. Once exosomes are released from the cell where they originated, they enter a recipient cell through various pathways such as fusion, receptor-mediated endocytosis, macropinocytosis, and phagocytosis.
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:21EPS and iPS Cells in Disease Research
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...